The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas  by Jennings, William C. et al.
From
U
M
W
N
th
th
D
The
tio
Auth
Rep
U
w
The
to
m
0741
Cop
So
BY
http
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arteriovenous ﬁstulas
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Background: Arteriovenous ﬁstulas (AVFs) are recommended for hemodialysis access when possible. A noncannulatable
but otherwise well functioning AVF leads to prolonged catheter dependency and frustration for the patient and the renal
health care provider team. Difﬁcult cannulation patients include obese individuals in whom cannulation sites are too deep,
and others with vein segments that are short, tortuous, or otherwise difﬁcult to palpate. The Venous Window Needle
Guide for Salvage of AV Fistulae (SAVE) trial was designed to evaluate the efﬁcacy and safety of the Venous Window
Needle Guide (VWING; Vital Access Corp, Salt Lake City, Utah) device for salvage of such noncannulatable AVFs that
are otherwise functional.
Methods: The SAVE study included patients with an established and otherwise mature AVF, in whom an additional
procedure would otherwise be necessary to establish reliable cannulation. The VWING is a single-piece titanium device
that allows repeated access of an AVF through a single puncture site (buttonhole technique). Inclusion criteria included
mature AVFs 6.0 to 15.0 mm in depth with multiple failed attempts at cannulation or where the access could not be
palpated. The devices were implanted subcutaneously and sutured to the anterior wall of the mature ﬁstula. Study end
points were reliable and successful cannulation and avoidance of adverse events during the 6-month follow-up, implant
technical success, and clinical cannulation success.
Results: Enrollment included 54 patients at 11 trial sites with implantation of 82 VWING devices. Body mass index was
26 to 50 (median, 36), 40 (74%) patients were female, and age was 17 to 84 (median, 59) years. Forty (74%) individuals
were diabetic. Thirty-three (61%) patients were white, 16 (30%) black, and 10 (18%) patients were Hispanic, Paciﬁc
Islander, or Native American. Three patients were excluded from data analysis for reasons unrelated to the device.
Successful AVF access was achieved using the VWING in 49 (96%) of the 51 patients evaluated. The rate of device-related
serious adverse events was 0.31 per patient-year; each event was resolved leaving the AVF functional. The rates of sepsis
and study-related interventions were 0.04 and 0.65 per patient-year, respectively. There were no study-related deaths.
One device was removed because of infection. The AVF survival rate at 6 months was 100%. The total number of study
days was 9497 and the estimated number of device cannulations was 4238.
Conclusions: The VWING was safe and effective in facilitating AVF cannulation for patients with an otherwise mature but
noncannulatable ﬁstula. Successful AVF access was achieved using the VWING in 49 (96%) of the 51 patients evaluated.
The AVF survival rate at 6 months was 100%. (J Vasc Surg 2014;60:1024-32.)the Department of Surgerya and Department of Nephrology,g
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4Arteriovenous ﬁstulas (AVFs) remain the gold standard
for hemodialysis vascular access. When compared with
catheter or graft dialysis access, AVFs have lower morbidity
and mortality rates in addition to lower costs.1,2 AVFs
require fewer hospitalizations and interventions. In addi-
tion, the functional vascular access life is longer for AVFs
compared with AV grafts and catheters.3
The increasing rate of obesity in the United States is
alarming, with >34% of Americans estimated to be obese.4
Creating a functional autogenous vascular access in over-
weight hemodialysis patients is often challenging. An
AVF might be successful according to outﬂow vein diam-
eter and ﬂow volume; however, the mature vein is often
too deep for reliable cannulation. In addition, the vein
might elongate and become tortuous, making palpation
more difﬁcult and successful cannulation impossible. Estab-
lishing a mature and functional AVF in such patients is
more complex and frequently requires an additional opera-
tion. The National Kidney Foundation Kidney Disease
Fig 1. a, The Venous Window Needle Guide (VWING; Vital Access Corp, Salt Lake City, Utah). The cannulation
device is comprised of a single piece of titanium that allows repeated access of an arteriovenous ﬁstula (AVF) through a
single puncture site (buttonhole technique). b, The schematic image shows the VWING sutured to the anterior AVF
wall using the eight suture slots. Cannulation is allowed using the buttonhole technique 3 weeks after implantation. c,
Each VWING device is 17.7 mm in length and available in 7 and 9 mm widths for variation in vessel diameter. AVF
depth variation is accommodated by available 4-, 6-, 8-, and 10-mm heights. All images were provided by and
reproduced with permission of Vital Access Corporation.
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endorse the “Rule of 6s,” when the AVF is $6 mm in
diameter (with tourniquet in place), #6 mm deep, and
with access ﬂow $600 mL/min.1,2 In addition, a func-
tional cannulation zone length of 6 inches is frequently rec-
ommended. A mature, well functioning AVF that is
noncannulatable offers no beneﬁt and leads to prolonged
catheter dependency with frustration for the patient and
the health care provider team.
The Venous Window Needle Guide for Salvage of AV
Fistulae (SAVE) clinical trial was designed to evaluate the
efﬁcacy and safety of the Venous Window Needle Guide
(VWING; Vital Access Corp, Salt Lake City, Utah) device
for salvage of a noncannulatable AVF that is otherwise
functional. The SAVE trial included patients with an estab-
lished and otherwise mature AVF, where an additional pro-
cedure would be required to establish reliable cannulation
because existing sites were too deep, or the AVF was too
short or not palpable for successful cannulation. The initial
experience using the VWING in humans found the device
to be safe and effective.5Device conﬁguration. The VWING is a single
component, titanium device that allows repeated access
of an AVF through a single puncture site (buttonhole can-
nulation technique). The device incorporates a broad fun-
nel conﬁguration that provides a target that directs the
needle to a cannulation window and the vessel wall.
A palpable cannulation ridge facilitates reliable localization
of the device (Fig 1, a). Through a small incision, the
device is sutured to the vein using slots at the periphery of
the device (Fig 1, b). The VWING vessel interface surface is
coated with titanium beads to promote ingrowth of vessel
wall tissue. The devices are each 17.7 mm in length and
available in 7 and 9 mm widths and 4, 6, 8, and 10 mm
heights (Fig 1, c) to accommodate varying AVF depths and
diameters.
METHODS
The SAVE study design was a prospective, multicenter,
single-arm evaluation of the VWING. Patients were consid-
ered when an additional procedure would otherwise be neces-
sary to establish reliable cannulation. In addition to physical
Table I. Venous Window Needle Guide for Salvage of AV Fistulae (SAVE) study inclusion and exclusion criteria
Inclusion criteria synopsis Exclusion criteria synopsis
AVF is uncannulatable in upper arm, forearm cephalic vein
outﬂow, or previously transposed basilic or brachial vein
outﬂow per the patient’s nephrologist and vascular access
surgeon
The AVF is a nontransposed basilic or brachial vein outﬂow AVF
Hemodialysis $1 month three times per week Patient <18 years of age, pregnant, body mass index >50, known
bleeding or coagulation disorder, active malignancy
AVF $5 mm at the planned site of device attachment AVF access stenosis or thrombosis within 1 month
Buttonhole cannulation is appropriate for the patient Skin infection, hypersensitive skin, or skin allergies at the potential
implant sites
No clinically signiﬁcant ﬂow abnormalities with ﬁstula ﬂow
$400 mL/min
Active systemic infection or positive blood culture present
A second vascular access surgeon, not involved with the study, has
also evaluated the subject’s eligibility and determined the AVF
to be uncannulatable per the protocol criteria
The AVF has undergone a major revision such as DRIL or PTFE
segment insertion, banding, aneurysm repair, etc
AVF was deemed ‘uncannulatable’ if the AVF was 6 to 15 mm in
depth at the required VWING access site(s), and at least one of
the following apply:
(1) Three or more failed access attempts within six
consecutive sessions
(2) At least two inﬁltrations (recurrent after period of rest)
that prevented dialysis
(3) The ﬁstula cannot be palpated to locate and deﬁne its
margins
(4) The ﬁstula is too tortuous to be cannulated
(5) The ﬁstula is only cannulatable in a segment that is too
short to appropriately accommodate two needles
(6) An aneurysm exists resulting in the ﬁstula being too
short to appropriately accommodate two needles
(7) The entire AVF is in the range of 6 mm to 15 mm in
depth
Signiﬁcant cardiovascular event/intervention such as myocardial
infarction, angioplasty, or stent placement within the previous
12 months; signiﬁcant peripheral vascular disease requiring a
major intervention within the previous 12 months; signiﬁcant
neurovascular event such as stroke or major intervention within
the previous 12 months; uncontrolled major symptomatic
medical problem, eg, undiagnosed severe pain, metabolic
disturbance, fever, etc; likelihood of poor compliance with
required dialysis protocol; mental incapacity; inability to
understand treatment instructions; currently participating in
another investigational drug or device study that clinically
interferes with the end points of this study
Patient’s life expectancy is $1 year Known or suspected allergy to titanium
AVF, Arteriovenous ﬁstula; DRIL, distal revascularization and interval ligation; PTFE, polytetraﬂuoroethylene; VWING, Venous Window Needle Guide
(Vital Access Corp, Salt Lake City, Utah).
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maturation including vein depth, diameter, and ﬂow volume.
After preliminary screening by the implanting surgeon, all
data including ultrasound images, were re-evaluated by an in-
dependent vascular surgeon and an on-site nephrologist. In-
clusion and exclusion criteria are shown in Table I.
Informed consent was obtained from each patient.
Patients were evaluated by the surgeon 3 to 5 weeks
postoperatively to approve cannulation initiation, and in
follow-up visits 3 and 6 months after surgery. Each
follow-up visit included physical and ultrasound examina-
tions. Initial cannulation was allowed as soon as 3 weeks af-
ter implantation with establishment of buttonhole
cannulation technique through the VWING(s). Each sub-
ject served as their own control by ability to cannulate a
previously uncannulatable ﬁstula with prescribed dialysis
through the VWING device.
The primary study objective was to access the ﬁstula
through the VWING device within 3 months after the
implant procedure, achieving the prescribed dialysis blood
ﬂow. Secondary objectives included implantation success,
initial cannulation within 43 days of the implant procedure,
and cannulation with a blunt (buttonhole) needle after 12or fewer sharp needle cannulations. The primary safety end
point was the occurrence of device- or procedure-related
adverse events during the 6-month follow-up period adjudi-
cated by the independent clinical events committee (CEC).
The independent CEC was comprised of two vascular sur-
geons and one nephrologist. Eleven clinical sites participated
with institutional review board approval obtained at each
site. Patients were enrolled into the study from December
2011 through December 2012 with ﬁnal patient follow-up
visits in June 2013. The studywas sponsored by theVital Ac-
cess Corporation under an Investigational Device Exemp-
tion (clinicaltrials.gov NCT01471041). Food and Drug
Administration approval was granted for the VWING in
September 2013 with indication for use as an access device
accessory on AVFs for hemodialysis procedures using a con-
stant site or “buttonhole” method of needle insertion.
Primary AVF patency was deﬁned as the time of unin-
terrupted patency without intervention after VWING im-
plantation. Primary assisted patency was the time of
uninterrupted patency after VWING implantation when
any interventional procedure was necessary. Cumulative
(secondary) patency was the period from VWING implan-
tation when AVF patency was interrupted by thrombosis,
Fig 2. The photo shows a Venous Window Needle Guide
(VWING; Vital Access Corp, Salt Lake City, Utah) device sutured
to the anterior surface of the ﬁstula just before closure of the
incision. The anterior surface of the ﬁstula was exposed, however,
the vein was otherwise left undisturbed.
Fig 3. A limited (focal) lipectomy is shown in this photo. The
excision of the small segment of adipose tissue was necessary at the
proximal Venous Window Needle Guide (VWING; Vital Access
Corp, Salt Lake City, Utah) site to ensure easy palpation of the
device for reliable cannulation.
Fig 4. The photo shows an arteriovenous ﬁstula (AVF) 3 weeks
after implantation of two Venous Window Needle Guide
(VWING; Vital Access Corp, Salt Lake City, Utah) devices at the
time of initial cannulations. The arrows indicate the easily palpated
cannulation ridges. In most patients, prompt AVF access and
conversion to blunt needles was allowed.
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cess or until completion of the study period.
Statistical analysis. Population demographic charac-
teristics, clinical history, risk factors, and preprocedure
data were included in the analysis. The ﬁstula salvage rate
was deﬁned as the ability to cannulate and dialyze as pre-
scribed through the subject’s previously uncannulatable
AVF using the VWING within 3 months after implant.
A minimal AVF salvage rate target of 37% was speciﬁed
in the study design.6 A one-sided exact binomial test at
the 0.025 signiﬁcance level was used with the ﬁstula
salvage rate summarized via count, percentage, and one-
sided exact 97.5% conﬁdence limit. The analysis was per-
formed using SAS version 9.3 software (SAS Institute Inc,
Cary, NC).
Surgical technique. The procedures were generally
performed on an outpatient basis using local anesthetic
and sedation. Each patient received a single dose of a
ﬁrst-generation cephalosporin before the procedure. Ul-
trasound was useful in conﬁrming the selected implant site
and planning the incision(s). The most frequently used
incision shape was a hockey stick (curved) incision, 4-5 cm
in length (Fig 2). The incision adequately exposed the
vessel and allowed for suturing of both sides of the device.
The anterior surface of the ﬁstula was exposed, however,
the vein was otherwise left undisturbed. The VWING was
secured to the vein wall with nonresorbable vascular suture.
Size 4-0 through 6-0 was speciﬁed in the protocol, how-
ever, most surgeons used 6-0 polypropylene suture. The
device was aligned longitudinally along the axis of the vein
(65) and oriented perpendicularly to the skin surface
(65). Each VWING was positioned such that the incision
and eventual scar would not interfere with the palpation
ridge and the skin cannulation site. Device palpability was
rated by the surgeon as “easy” (device features palpable)or “moderate” (device palpable). A limited lipectomy
was allowed by protocol if needed to ensure reliable
palpation of the device (Fig 3). The incisions were closed
with interrupted or running absorbable suture and an
Table II. Medical comorbidities
Patients, No. Percentage (N ¼ 54)
Hypertension 49 91
Hemodialysis catheter 43 80
Diabetes 40 74
Obesity 36 67
Previous AVF 29 54
Anemia 28 52
Heart failure 13 24
Coronary artery disease 13 24
Respiratory disease 12 22
Amputation 8 15
Peripheral vascular disease 6 11
Previous graft 6 11
Stroke 6 11
Cardiomyopathy 5 9
Myocardial infarct 4 7
Smoker 4 7
Cancer 4 7
Central venous stenosis 3 6
Hypercoagulability 1 2
AVF, Arteriovenous ﬁstula.
Table III. Device size implanted
Device size Devices, No. (%) (N ¼ 82)
4 mm  7 mm 4 (5)
6 mm  7 mm 31 (38)
8 mm  7 mm 41 (50)
10 mm  7 mm 1 (1)
4 mm  9 mm 0 (0)
6 mm  9 mm 2 (2)
8 mm  9 mm 2 (2)
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tourniquets were not used.
Cannulation technique. Patients were evaluated for
initial cannulation at a 3-week follow-up. The decision
for initial cannulation for individual patients was made by
the surgeon. Vessel diameter, AVF ﬂow volume, surgical
site healing, and device palpability were all considered by
each surgeon, although speciﬁc criteria were not speciﬁed
in the protocol. On approval, the dialysis clinic staff was
trained by Vital Access proctors. The cannulation
training included an understanding of the shape and
position of the VWING implant, how to identify the skin
puncture site, the use of the proper needle, and cannu-
lation site disinfection using the “double prep” technique
for buttonhole cannulation.7 Timing of the conversion to
blunt needles was left to the discretion of the clinic with
all cannulation events recorded during each treatment
session.
RESULTS
Patient demographic characteristics and screening.
Eighty-two devices were implanted in 54 patients. The me-
dian age was 59 (range, 17-84) years, and 40 (74%) patients
were diabetic. The median body mass index was 36 (range,
26-50) and 40 (74%) of the patients were female. Thirty-
three (61%) individuals were white, 16 (30%) black,
5 (9%) Hispanic, 4 (7%) Paciﬁc Islander, and 1 (2%) Native
American. Comorbidities are shown in Table II. AVF
conﬁgurations were 34 (63%) brachiocephalic, 15 (28%)
radiocephalic, 4 (7%) transposed brachiobasilic, and one
forearm reversed ﬂow ﬁstula. Thirty-three (61%) patients
had previously functional AVFs that had become uncan-
nulatable and 21 (39%) were never able to be cannulated.
The median age of the AVF was 4.8 (range, 1.0-12.0)
months. Ultrasound measurements of the AVFs at the time
of screening of all prospective device sites demonstrated amedian diameter of 7.8 (range, 4.1-19.1) mm, depth of
8.9 (range, 4.8-15.0) mm, and an AVF ﬂow rate of 959
(range, 186-6541) mL/min.
Device implantation. Technical implantation success
of the VWINGs with proper attachment, alignment, and
palpability was achieved for 82 of 82 (100%) devices.
Twenty-six patients (48%) received one VWING device
and 28 individuals (52%) received two devices for an
average of 1.5 devices per patient. A single device im-
plantation was appropriate for patients initially evaluated
in whom only one successfully cannulated site could be
established and the remainder of the access otherwise
met the protocol requirements for a noncannulatable
second needle site. VWINGs were implanted in the up-
per arm in 38 patients (70%). There were no adverse
events associated with the implant procedures. A single
suture repair of an AVF was performed during suturing
of one device to the vessel wall without effect on the
ﬁstula.
Local anesthesia with monitored sedation was used in
45 (83%) patients, general anesthetic was used in 6 (11%)
patients and 3 (6%) individuals received a regional block.
All implant procedures except one were performed as
same-day surgeries. The median surgical time for proce-
dures was 38 (range, 21-65) minutes for one device and
78 (range, 37-120) minutes for two devices. The median
skin incision length was 4.0 (range, 2.0-10.0) cm. The
10-cm incision length was made such that two devices
were implanted within the same exposure.
Device palpability at the time of the implant procedure
was rated as “easy” for 76 (93%) devices and “moderate”
for 6 (7%) devices. Two device sizes made up nearly 90%
of the devices used in the study: 8 mm  7 mm (50%)
and 6 mm  7 mm (38%) (Table III). A limited lipectomy
at the implant site was necessary for 61 (74%) of the
VWINGs placed. The median tissue thickness above the
device was 3.0 (range, 1.5-10.0) mm at the time of skin
closure. When the surgeon evaluated the VWING to be
“moderately palpable” at the completion of the wound
closure, the median tissue thickness over the devices was
8.0 (range, 2.5-10) mm. The surgeon’s ultrasound evalua-
tion just before the procedure was helpful in selecting the
best site and planning the incision. The implantation proce-
dure was relatively simple and straightforward with no new
technical skills needed. Device placement was readily
learned with a single procedure.
Fig 5. The number and percentage of Venous Window Needle
Guide (VWING; Vital Access Corp, Salt Lake City, Utah) devices
in use during the 6-month study period.
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lation within 3 months, was achieved in 75 of 79 (95%) de-
vices, including 27 (96%) arterial site and 48 (94%) venous
site devices. This result is signiﬁcantly greater than the pre-
established minimal clinical success rate target of 37%
(P < .001).7 Three enrolled subjects (three devices) were
excluded from primary end point analysis for reasons un-
related to the device. One patient died of an unrelated
cause before cannulation and two other patients chose not
to continue participation in the study after device implan-
tation. Of the 79 remaining devices, four were not suc-
cessfully cannulated; three because of excessive depth and
one was severely canted.
Because the VWING is intended for use during the life
of the ﬁstula, device use at 3 months and 6 months after
implantation were analyzed. Seventy-three of 79 devices
(92%), including 26 (93%) arterial site and 47 (92%)
venous site devices, were accessed at 3 months. In addition
to the continued nonuse of the four devices for which a
ﬁrst cannulation was not achieved, two devices were not
in use at 3 months because of painful cannulation in one
and difﬁcult cannulation in the other. Median time to
initial cannulation was 36 (range, 15-91) days.
At 6 months, 77 devices were evaluated for use; two
devices were censored after 3 months in a patient who
died of causes unrelated to the study. Sixty-six of the 77
evaluable devices (86%) were in use, including 23 (85%)
arterial site and 43 (86%) venous site devices. In addition
to the six devices not in use at 3 months, ﬁve additional de-
vices were unusable at 6 months: one device pending reso-
lution of a site infection, one device was explanted because
of cannulation pain, one device was explanted because of
infection, and two devices were explanted because of difﬁ-
cult cannulation (Fig 5).
Blunt needle (buttonhole) cannulation was achieved in
68 of the 75 cannulated device sites (91%). The median
number of sharp needle cannulations before blunt needle
cannulation was 14 (range, 3-26). At 3 and 6 months,
44 (60%) and 57 (80%) of device sites in use were accessed
with blunt needles, respectively.Adverse events and interventions. The VWING can-
nulation guides were implanted in 54 patients for a total of
9497 study days (26.0 patient-years). Eighty-two devices
were implanted for a total of 14,172 days (38.8 device
years) with an estimated 4238 device cannulations.
Table IV summarizes the serious adverse events
(SAEs). There were 8 device-related SAEs involving 7
(13%) patients. The device-related SAE rate was 0.31 per
patient-year. Each event resolved, leaving the ﬁstula intact
and functional. Stenosis of an AVF at a VWING site was
adjudicated as serious in one patient because of a recurrent
event. The stenosis was successfully dilated, but required
retreatment 2 months later and subsequently remained
widely patent without further recurrence. Additionally
three stenoses at three separate device sites were adjudi-
cated to be nonserious and resolved using angioplasty.
Four patients had ﬁve devices abandoned or explanted
because of a canted device, deep device placement, or can-
nulation pain. Each of these AVFs remained functional.
Thirty-nine interventions to maintain hemodialysis
capability were necessary in 24 (44%) patients; an overall
occurrence rate of 1.5 interventions per patient-year.
Seventeen of the 39 interventions were judged by the
CEC as associated with the device site; 0.43 per device-
year. Study-related interventions are shown in Table V
and were associated with the clinical diagnoses of stenosis,
seroma, infection, device canting, cannulation difﬁculty,
and cannulation pain. A single patient required a second
study-related intervention (stenosis) and was treated
successfully.
Sepsis resulting from infection of a VWING site
occurred in a single patient. This device was removed and
a local superﬁcialization was performed, leaving the ﬁstula
intact. The rate of sepsis was 0.04 per patient-year. Super-
ﬁcial access site cellulitis was reported in three patients as
non-SAEs. Each of these sites had focal redness with
some induration at the cannulation site. The diagnosis of
infection in each case was presumptive because no material
was present to culture. None of these patients had systemic
symptoms and none were hospitalized. All three sites were
rested, the patients received antibiotics, and cannulation
was resumed without relapse of the symptoms. The rate
of site infection was 0.08 per device-year or 0.0007 per
cannulation.
No subjects developed access-related hand ischemia.
There were no study-related deaths, but two subjects
died of causes (cardiac arrest) unrelated to the study. There
were no unanticipated adverse events, interventions, or
cannulation complications. Primary, primary-assisted, and
cumulative (secondary) patency rates were 61%, 100%,
and 100%, respectively, at study completion. The VWING
site-associated contribution to loss of ﬁstula primary
patency was 14% at 6 months (Fig 6).
DISCUSSION
Obesity in the United States has neared epidemic pro-
portions, with more than 35% of adult individuals found to
have a body mass index of $30.4 Men and women are
Table IV. Summary of clinical events committee (CEC)-adjudicated, study-related serious adverse events (SAEs)
Diagnosis Treatment Status
Study days
to event
Patients,
No. (%)
Related to
device
Related to
procedure
Cannulation pain Device removal
168 days after implant
Resolved 97 1 (2) Probable Deﬁnite
Stenosis of
AVF >50% at
the VWING site
Fistuloplasty Resolved, ability
to dialyze
restored
92 1 (2) Deﬁnite Undetermined
Pain at VWING site Device removal after study Resolved 179 1 (2) Deﬁnite Deﬁnite
Sepsis Antibiotics and
device removal
Resolved 133 1 (2) Deﬁnite Deﬁnite
Difﬁcult cannulation Device removal
127 days after
implant
Resolved 106 1 (2) Probable Probable
Stenosis of AVF >50%
at the VWING site
Fistuloplasty Resolved, ability
to dialyze
restored
140 1 (2) Deﬁnite Unrelated
Stenosis of
AVF >50%
at the VWING site
Fistuloplasty Resolved, ability
to dialyze
restored
205 1 (2) Deﬁnite Unrelated
Poor buttonhole
cannulation
candidate
Removal of
devices and
superﬁcialization
of ﬁstula 142 days
after implant
Resolved 41 1 (2) Deﬁnite Deﬁnite
AVF, Arteriovenous ﬁstula; VWING, Venous Window Needle Guide (Vital Access Corp, Salt Lake City, Utah).
Table V. Study-related interventions
Diagnosis Treatment
Pain at the VWING site Explant device and ﬁstula
superﬁcialization
Intraﬁstula stenosis at the
VWING site
Fistuloplasty
Seroma; ﬂuid at site at 3-week
follow-up visit
Percutaneous needle aspiration
of ﬂuid collection in clinic
Infection at the VWING site Excise tissue surrounding
device, antibiotics
Sepsis Explant the device, antibiotics
Unable to cannulate the
implanted devices
Explant of devices and ﬁstula
elevation
“Knot-like” swelling at incision
site, soft, tender to touch
Aspirated seroma
High-grade stenosis at VWING
site
Fistuloplasty
Recurrent stenosis at VWING
site
Fistuloplasty
Stenosis at the arterial VWING
site
Fistuloplasty
Intraﬁstula stenosis at the
venous VWING site
Fistuloplasty
Venous site device canted and
uncannulatable
New venous site implant
VWING, Venous Window Needle Guide (Vital Access Corp, Salt Lake City,
Utah).
Fig 6. The Venous Window Needle Guide (VWING; Vital
Access Corp, Salt Lake City, Utah) site-associated and non-
VWING site-associated contribution to loss of ﬁstula primary
patency are shown in the Kaplan-Meier vascular access patency
display. Cumulative (secondary) and assisted patency rates were
100% during the study period. The number of patients at risk for
each group is indicated at the bottom of the graph. AVF, Arte-
riovenous ﬁstula; SAVE, Venous Window Needle Guide for
Salvage of AV Fistulae.
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an autogenous access created in addition to commonly
requiring subsequent procedures to allow reliable cannula-
tion.8-10 Ironically, overweight individuals often have
adequate veins in the superﬁcial venous system that are
too deep to be accessed and therefore are spared repeated
venipuncture and intravenous cannulations. An AVF mightbe constructed that would be functional except for difﬁcult
cannulation because of vein depth. Kats et al found that
AVFs might be successfully constructed in obese patients
although long-term outcomes were signiﬁcantly worse
because of greater cumulative (secondary) access failure
rates.10 Current practice for establishing a functional AVF
in these challenging patients often requires another more
complex procedure or a planned secondary procedure.11-13
Fig 7. A Venous Window Needle Guide (VWING; Vital Access
Corp, Salt Lake City, Utah) buttonhole site after 6 months of
regular cannulation is shown (circled). The distal (arterial) site has
been cannulated. This typical VWING buttonhole site was small
and free of inﬂammation or edema, likely because of the ease and
reliability of cannulation.
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atic in these challenging patients because of the outﬂow
vein length expended in repositioning the vein. An extensive
lipectomy procedure or other surgical revision also consti-
tuted a major secondary procedure. Patency after ﬁstula
elevation procedures can allow an uncannulatable ﬁstula to
be used, however, long-term patency might be decreased.
Cannulation might also be difﬁcult in nonobese pa-
tients. Short available cannulation segments, aneurysms,
and tortuosity are just some of the challenges for the dial-
ysis staff. Parisotto et al found that 66% of >7000 patients
studied were cannulated improperly using the area (cluster)
cannulation technique.14
The SAVE study population had a greater rate of
obesity (78% vs 33%), and more female (74% vs 44%) and
diabetic patients (74% vs 63%) compared with the U.S.
Renal report (U.S. Renal Data System) and Dialysis Out-
comes and Practice Patterns Study (DOPPS) studies.3,15
These groups have higher rates of primary and secondary
ﬁstula failure leading to a higher rate of required interven-
tions, yet 30 of the 54 SAVE study ﬁstulas (56%) required
no interventions to maintain patency, similar to expecta-
tions for the general dialysis population.15-17 All 51 living
study patients used their study ﬁstula for dialysis at
6 months. Cumulative access patency was 100% during
the study period, a signiﬁcantly greater AVF survival rate
than expected from past reports.17-19
Patients experienced an average of 57 cannulations
(median, 61; range, 1-76). A total of 4238 estimated can-
nulations resulted in only a single device that required
explantation because of infection. Removal of the device
was uncomplicated without repair needed to the AVF site
and did not result in loss of the ﬁstula. The patient’s
AVF was superﬁcialized and remains functional at this
time. Three sites were judged to have developed cellulitis
during the study. The U.S. Renal Data System reported
“infection of access” rate for native AVFs is 0.18 per
patient-year compared with the SAVE study site infection
rate of 0.12 per patient-year.15
The opportunity for early cannulation (3-6 weeks in 33
subjects) is an important beneﬁt when considering AVF
success. Prolonged or failed AVF maturation are common
problems noted in other studies.17-19 Inability to reliably
cannulate AVFs or the need for secondary procedures
with longer healing times are frequent issues. The
VWING’s functional maturation rate was 96% and the
mean maturation time of the VWING site was 40 days.
This shortened time to access and high functional rate
should result in fewer catheter dialysis days and the associ-
ated complications and hospitalizations.
Buttonhole cannulation in the SAVE study was very
successful, with 92% of these uncannulatable AVFs used
for reliable buttonhole cannulation. We subjectively
observed buttonhole sites that were free from inﬂammation
or edema and the patients and staff believed cannulation
was reliable and nontraumatic (Fig 7). This study included
43 dialysis units, with a broad array of nursing and technol-
ogist cannulators, demonstrating that use of the device andthe buttonhole technique speciﬁed are broadly applicable
for use in dialysis clinics. The 43 dialysis units involved in
the study were not selected with any bias toward buttonhole
experience or expertise. No patient received all cannulations
by a single provider. Some physicians have reservations
regarding buttonhole cannulation with concern about cellu-
litis or infection. Clinical studies have varied, with some re-
ports ﬁnding improved ﬁstula survival because of reduced
trauma and inﬂammation when the buttonhole cannulation
technique is used, and other investigators noted an
increased rate of infection when compared with the rope-
ladder technique.6,20-24 The encouraged rigorous skin prep-
aration and careful sterile technique used in this study might
offer insight into the higher complication rates reported
from other centers, further solidifying the buttonhole tech-
nique as a safe and reliable method of cannulation. No an-
eurysms developed in the short follow-up period and we
speculate that the precise buttonhole entry point into the
AVF might well decrease the number of aneurysms with
further long-term follow-up.
During VWING implantation, the surgeon selected the
appropriate device based on the depth of the vessel and
adjusted the tissue thickness with a focused lipectomy if
necessary, specifying the device to be either easily or
moderately palpable. The key factors that determined the
level of palpability were device height and the thickness
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noncannulatable devices explanted, perhaps because of
the selection of inadequate device height for the ﬁstula
depth at the original implant procedure. Both devices
had been rated as “moderately palpable.” Overall, the sur-
gical palpability rating was “easy” for 93% of the devices.
Further application of the device might include place-
ment at other noncannulatable sites such as the superﬁcial
portion of the basilic vein near the elbow, safely away from
the brachial neurovascular bundle, thereby avoiding a later
transposition or revision procedure. Additional studies are
needed to evaluate the use of the VWING in a broader
AVF population to facilitate buttonhole cannulation with
hope of prolonged ﬁstula patency.
CONCLUSIONS
The VWING device is safe and effective for facilitating
AVF cannulation in patients with an otherwise mature but
noncannulatable ﬁstula. Successful AVF access was
achieved through the VWING in 49 (96%) of the 51
patients evaluated. The AVF survival rate at 6 months
was 100%. The device is an effective cannulation aid for
accessing multiple types of newly matured and existing
AVFs at a wide range of cannulation site depths. The device
was shown to be useful in the creation and continued can-
nulation of a safe and reliable buttonhole access site.
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